Objectives To establish a James Lind Alliance (JLA) Priority Setting Partnership (PSP) to identify research priorities relevant to the health and social care needs of adults with lived experience of recent and/or historical sexual violence/abuse.
Participants Adults (aged 18+ years) with lived experience of sexual violence/abuse (ie, ‘survivors’) were consulted for this PSP, alongside healthcare and social care professionals who support survivors across the public, voluntary, community, independent practice and social enterprise sectors.
Methods In line with standard JLA PSP methodology, participants completed an initial online survey to propose research questions relevant to the health and social care needs of survivors. Research questions unanswered by current evidence were identified, and a second online survey was deployed to identify respondents’ priorities from this list. Questions prioritised through the second survey were presented at a consensus meeting with key stakeholders to agree the top 10 research priorities using a modified nominal group technique approach.
Results 223 participants (54% survivors) provided 484 suggested questions. Seventy-five unique questions unanswered by research were identified and subsequently ranked by 343 participants (60% survivors). A consensus meeting with 31 stakeholders (42% survivors) examined the top-ranking priorities from the second survey and agreed the top 10 research priorities. These included research into forms of support and recovery outcomes valued by survivors, how to best support people of colour/black, Asian and minority ethnic and lesbian, gay, bisexual, transgender, and queer (LGBTQ+) survivors, improving access to high-quality psychological therapies, reducing public misconceptions/stigma, the impact of involvement in the criminal justice system on well-being, and how physical and mental health services can become more ‘trauma informed’.
Conclusions These research priorities identify crucial gaps in the existing evidence to better support adult survivors of sexual violence and abuse. Researchers and funders should prioritise further work in these priority areas identified by survivors and the professionals who support them.
- MENTAL HEALTH
- FORENSIC MEDICINE
- HEALTH SERVICES ADMINISTRATION & MANAGEMENT
- PUBLIC HEALTH
Data availability statement
Data are available upon reasonable request. Data can be requested by contacting the project leads: Dr Filippo Varese and Dr Rabiya Majeed-Ariss.
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Twitter @afronalysis, @concettaperot
Contributors Project leadership and coordination—FV and RM-A. Design and preparation of project protocol—FV, RM-A, CW, EL and LaM. James Lind Alliance advice and chairing of Steering Group—TG. Data collection—EY, LoM, EA, IP, KM and CC. Question verification and evidence checking—RM-A, FV, EA, LT, A-MJ, CM and CP. Survey data analysis—FV, RM-A, IP, EA, CC and KM. Contribution to Steering Group activities (eg, protocol ratification, piloting and sign-off survey questions, selection of final uncertainties for prioritisation)—CW, EL, JC, EH, A-MJ, SM, CM, CP, SS, DT and LT. Initial draft of manuscript—FV, CC and KM. Revising and final approval of manuscript—all authors. Guarantor of the research- FV.
Funding The project was supported via internal funding from the University of Manchester’s Division of Psychology and Mental Health and the Centre for New Treatments and Understanding in Mental Health (CeNTrUM). Additional funding to support the involvement of survivors in this PSP has been gathered through a crowdfunding campaign supported by the University of Manchester crowdfunding team.
Competing interests Non-commercial interests: FV and RM-A have received research funding from the UKRI Violence, Abuse and Mental Health Network focusing on the long-term needs of survivors of sexual violence. FV and EL received several research grants from the National Institute of Health Research for the development and evaluation of psychological therapies for individuals with severe mental health difficulties (Advanced Fellowship Programme; Research for Patient Benefit Programme, Health Technology Assessment Programme, and the Health Service & Delivery Research Programme; and Postdoctoral Fellowship Programme and Development and Skills Enhancement Award), including trials focusing on the mental health needs of trauma survivors. EH is the director of The Lighthouse, an NHS service providing health, therapy, advocacy and child-friendly justice for children who experience sexual abuse in north London. All other authors have no non-commercial interests to declare. Commercial interests: EH is the director of a management consultancy specialising in the fields of whole system transformation and child sexual abuse services (Harewood Consultancy). All other authors have no commercial interests to declare.
Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.